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Abstract
After decades of Alzheimer’s disease (AD) research, the development of a definitive diagnostic test for this disease has
remained elusive. The discovery of blood-borne biomarkers yielding an accurate and relatively non-invasive test has been a
primary goal. Using human protein microarrays to characterize the differential expression of serum autoantibodies in AD
and non-demented control (NDC) groups, we identified potential diagnostic biomarkers for AD. The differential significance
of each biomarker was evaluated, resulting in the selection of only 10 autoantibody biomarkers that can effectively
differentiate AD sera from NDC sera with a sensitivity of 96.0% and specificity of 92.5%. AD sera were also distinguishable
from sera obtained from patients with Parkinson’s disease and breast cancer with accuracies of 86% and 92%, respectively.
Results demonstrate that serum autoantibodies can be used effectively as highly-specific and accurate biomarkers to
diagnose AD throughout the course of the disease.
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Introduction
Alzheimer’s disease (AD) is an increasingly prevalent and
devastating neurodegenerative disease with tremendous social and
economic costs, not only to the sufferers but also to caregivers and
families. It is the most common cause of dementia worldwide,
affecting over 5.4 million people in the United States alone, and
has seen a rapidly growing incidence in the aging population [1].
Hallmarks of AD pathology include amyloid-b deposition in
neurons, amyloid plaques, tau hyperphosphorylation, neurofibril-
lary tangles, synaptic loss, and progressive neurodegeneration [2–
4]. The disease can span decades and is thought to progress
unnoticed for 5–10 years before clear symptoms emerge and
clinical detection is possible using conventional means [5,6].
Accurate diagnosis of AD has proven to be difficult to achieve.
Current diagnostic practices include neuroimaging techniques,
behavioral history assessments, and neuropsychiatric tests [7]. None
of these methods by themselves or in combination provide for early
detection or yield high accuracy. There has been a great deal of
research emphasis on the search for blood-borne biomarkers
indicative of AD pathology, but most attempts have found only
limited success [7]. Other proposed tests have significant drawbacks
in the form of patient discomfort or excessive cost. The Alzheimer’s
communityisstillin dire need of adiagnostic method that is accurate,
relatively non-invasive, and inexpensive.
Our previous studies have shown that autoantibodies are
surprisingly numerous in human sera regardless of age or disease
[8,9]. Suspecting that these autoantibodies may play a role in
neurodegenerative diseases, we sought to determine if the presence
of ongoing pathology causes changes in the spectrum of
autoantibodies present in the serum. If so, then perhaps these
changes could be used to identify specific autoantibodies that are
useful as diagnostic indicators or biomarkers. Given the large
number of autoantibodies present in human sera, we utilized high-
throughput protein microarray technology to assess individual
autoantibody expression profiles. We searched for disease group-
and control group-specific variations in autoantibody expression
patterns in an effort to identify potentially useful diagnostic
biomarkers. Our results show that autoantibody expression
profiles, determined using protein microarray technology, can be
used to select a relatively small panel of useful autoantibody
biomarkers that can detect the presence of specific diseases such as
AD with great accuracy using only a small sample of blood.
Materials and Methods
Ethics Statement
Approval for the use of blood samples for this study was
obtained from the UMDNJ-Stratford Institutional Review Board.
Patient Samples
Serum samples from 50 AD subjects and 40 non-demented
controls (NDC) were obtained from Analytical Biological Systems, Inc.
(Wilmington, DE). 30 breast cancer (BC) serum samples and 29
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Asterand, Inc. (Detroit, MI). To represent different disease stages
reflecting disease severity, our AD serum pool contains samples
with Mini-Mental State Examination (MMSE) scores ranging
from 2–24. All samples were handled by standard procedures and
stored at 280uC. Diagnosis of AD was based on a medical
evaluation, neuropsychiatric testing, and on the National Institute
of Neurological and Communicative Disorders and the Alzhei-
mer’s Disease and Related Disorders Association criteria.
Demographic characteristics of the study population are shown
in Table 1.
Human Protein Microarrays
To identify autoantibodies in human sera, we used Invitrogen’s
ProtoArray v5.0 Human Protein Microarrays (Cat. No.-
PAH0525020, Invitrogen, Carlsbad, CA, USA), each containing
9,486 unique human protein antigens (www.invitrogen.com/
protoarray). All proteins have been expressed as GST fusion
proteins in insect cells, purified under native conditions, and
spotted in duplicate onto nitrocellulose-coated glass slides. All
arrays were probed and scanned according to the manufacturer’s
instructions using commercially prepared reagents. Briefly, micro-
array slides were blocked (Blocking Buffer, Cat. No. PA055,
Invitrogen) and then incubated with serum samples, diluted 1:500
in washing buffer. After washing, the arrays were probed with anti-
human IgG (H+L) conjugated to AlexaFluor 647 (Cat. No. A-
21445, Invitrogen). Arrays were then washed, dried, and
immediately scanned with a GenePix 4000B Fluorescence Scanner
(Molecular Devices, Sunnyvale, CA, USA).
Dot Blot Analysis
One ml volumes of purified recombinant human FRMD8
(0.2 mg/ml) and PTCD2 (0.1 mg/ml) proteins (Cat. No. TP307879
and TP315253, OriGene Technologies, Inc., Rockville, MD,
USA), were manually pipetted onto a nitrocellulose membrane.
The proteins were blocked in a 5% non-fat milk PBS-Tween
solution for one hour at room temperature (RT). The proteins
were then probed with human serum samples diluted 1:2000 for
one hour at RT. All sera were identical to those used to probe the
human protein microarrays. The dot blots were probed with anti-
human IgG (H+L) HRP conjugate antibody (Cat. No. 31410,
Thermo Fisher Scientific Inc., Pittsburgh, PA, USA) for one hour
at RT, incubated with ECL reagent (Cat. No. 34096, Thermo
Fisher Scientific Inc., Pittsburgh, PA, USA) for one minute, and
then exposed to X-ray film at various intervals.
Data Analysis
The fluorescence data for each microarray was acquired by
Genepix Pro analysis software after scanning, and then synced with
Invitrogen’s lot-specific Genepix Array List (GAL) files. The resulting
Genepix Results (GPR) files were then imported into Invitrogen’s
Prospector 5.2 for analysis. All data is MIAME compliant and have
been deposited in NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number GSE 29676.
The ‘‘group characterization’’ and ‘‘two - group comparison’’
features in the IRBP Toolbox allowed for M-statistical analysis of
autoantibody expression. Sorting detectable autoantibodies by
difference of prevalence between AD and NDC groups in
descending order, we selected the top 10 as our potential
diagnostic biomarkers.
The selected biomarkers were re-verified as significant by
Predictive Analysis for Microarrays (PAM) – an independent algorithm
relying on nearest shrunken centroid analysis to identify proteins
acting as significant class-differentiators. The predictive classifica-
tion accuracy of the identified biomarkers was tested with Random
Forest (RF) using the default settings, another significance algorithm
run as an R package (v 2.12.1). In RF, partitioning trees are built
by successively splitting the samples according to a measure of
statistical impurity at a given node until terminal nodes are as
homogenous as possible. Classification accuracy for a given set of
diagnostic biomarkers is reported in a confusion matrix and
misclassification as an Out-Of-Bag (OOB) error score.
Results
Protein Microarrays Reveal That Autoantibodies Are
Numerous in Human Serum
To detect autoantibodies in sera, we probed protein microarrays
with individual serum samples (n=149) (Table 1). Results using
the standard Chebyshev Inequality p-value threshold of 0.05
suggest an average of over one thousand different autoantibodies
per serum sample; although the number varied widely from one
individual to the next (n=149, 111561096) (Table 2). This, along
with our previous work showing the presence of abundant
autoantibodies via western analysis [8,9], provides strong support
for a large number of autoantibodies in human sera. It appears
that this may be a generally unappreciated feature of the blood,
with a function that remains to be elucidated.
Selection of Autoantibody Biomarkers for AD Diagnosis
A total of 90 human serum samples (50 AD and 40 NDC) were
randomly assigned to either a Training or Testing Set composed of
25 AD and 20 NDC sera each; both containing equal proportions
of earlier- and later-stage AD samples as well as older and younger
controls. To identify potential diagnostic autoantibodies, we
probed protein microarrays, each containing 9,486 antigens, with
Training Set sera and analyzed the data as described in the
methods section (Fig. 1). Prospector analysis software determined
that 451 autoantibodies had a significantly higher prevalence in
the AD group than in the NDC group (p,0.01). We selected the
10 biomarkers that demonstrated the largest difference in group
prevalence between AD and NDC to serve as our diagnostic
indicators (Table 3). As an independent verification of the 10
biomarkers selected, we also utilized Predictive Analysis for Microarrays
(PAM) to re-evaluate our data [10]. PAM confirmed that the 10
biomarkers originally selected by Prospector were among the most
significant classifiers of AD and NDC.
Table 1. Demographics of serum donors.
Group n Age Sex MMSE
Mean Range (% male)
Alzheimer’s disease 50 78.5 61–97 40% 2–24
–Earlier-stage
1 35 78.7 61–97 43% 15–24
–Later-stage
2 15 78.0 65–94 33% 2–14
Non-demented Controls 40 40.4 19–86 82% –
–Older Control 20 57.7 51–86 100% –
–Younger Control 20 24.7 19–30 65% –
Parkinson’s disease 29 74.0 53–88 55% –
Breast Cancer 30 46.7 32–54 0% –
1Earlier-stage: AD patients with MMSE$15.
2Later-stage: AD patients with MMSE,15.
doi:10.1371/journal.pone.0023112.t001
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Analyses
To assess the Training and Testing set classification accuracies
of the 10 selected biomarkers, we used Random Forest (RF) [11]. RF
is a statistical algorithm which creates voting classes of decision-
making trees to evaluate the significance of each marker and
classify samples. Using our 10 biomarkers to ‘‘diagnose’’ the
Training Set (n=45; 25 AD and 20 NDC), RF had an overall
accuracy of greater than 93% [Out-of-Bag (OOB) Error 6.67%, a
positive predictive value (PPV) of 92.3%, and a negative predictive
value (NPV) of 94.7%]. When the 10 biomarkers were used to
classify the Testing Set sera (n=45; 25 AD and 20 NDC), which
played no part in the biomarker selection process, RF distinguished
AD samples from NDCs with a similar accuracy (prediction error
of 6.67%, PPV of 100.0%, and NPV of 87.0%).
Biomarker Performance in Different Sample
Demographics
When the 10 autoantibody biomarkers were used to classify all
AD and NDC samples combined (n=90; 50 AD, 40 NDC) using
RF, they did so with a 96.0% sensitivity and 92.5% specificity. We
also tested their performance in classifying samples from different
demographics: earlier-stage AD, later-stage AD, older controls,
and younger controls. The 10 biomarkers classified samples with
over 90% accuracy in all subgroups tested (Table 4). AD samples
were correctly differentiated from younger controls with high and
consistent accuracy, a common-sense indication of biomarker
credibility.
Distinction of AD From Other Diseases
One must be careful in the creation of a biomarker diagnostic to
ensure disease specificity. Therefore, we sought to differentiate AD
from other non-neurological and neurological diseases. We
acquired 30 breast cancer serum samples and used our 10 selected
diagnostic biomarkers to differentiate them from the 50 AD
samples. RF reported an OOB Error of 7.5% (PPV and NPV of
90.7% and 96.2%, respectively). These results are similar to those
of the AD versus NDC trials above and demonstrate no diagnostic
bias toward general disease.
We next sought to determine if it is possible to differentiate
between two closely related neurodegenerative diseases. For this,
we selected Parkinson’s disease (PD) because it shares much in
common with Alzheimer’s pathology [12,13]. There is also a
significant overlap (22%,48%) at the pathological and clinical
levels, making it difficult to clearly distinguish these two diseases by
conventional means alone [14,15]. Again, we utilized Prospector,
PAM, and RF to identify the most significant disease classifiers. We
determined that by using only five diagnostic biomarkers (Table 5),
it was possible to differentiate AD samples from PD samples with
over 86% accuracy (sensitivity=90.0%, specificity=79.3%). To
our knowledge, this is the highest efficiency ever achieved with
blood biomarkers to distinguish these closely related neurodegen-
erative diseases [15,16].
Dot Blot Confirmation of Potential Biomarkers
To further validate the differential expression of autoantibodies
detected with human protein microarrays, we carried out a
comparative dot-blot analysis using commercially-obtained, puri-
Table 2. Estimate of autoantibodies per sample group.
Sample Group (n) Median s Range
All Samples 149 920 1096 0–6389
Alzheimer’s disease 50 969.25 770 0–3311
–Earlier-stage 35 826.5 672 0–2805
–Later-stage 15 1321.5 865 110–3311
Non-demented controls 40 982 965 0–3585
–Older Controls 20 1066.25 896 32–2675
–Younger Controls 20 942.5 1050 0–3585
Parkinson’s disease 29 539.5 762 0–2585
Breast Cancer 30 884.5 1723 5–6389
doi:10.1371/journal.pone.0023112.t002
Figure 1. Biomarker selection and Training / Testing Analysis. Before biomarker selection, our total sample pool was split into two
randomized groups: the Training Set and Testing Set. Prospector and PAM statistical analyses were performed on the Training Set to identify the top
10 most significant autoantibody classifiers of AD and NDC. We then verified the diagnostic accuracy of these selected biomarkers by using Random
Forest to predict sample classification in the Training Set, Testing Set, and then both sets combined.
doi:10.1371/journal.pone.0023112.g001
Autoantibodies and Alzheimer’s Disease Diagnosis
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23112fied native proteins. We selected two of the most potent
differentiating antigens identified, PTCD2 and FRMD8, and
sought to verify their reactivity. The two proteins were spotted
onto nitrocellulose membrane and probed with identical sera to
that used on the microarrays. Results from both AD and NDC
sera show strong agreement in the relative intensities of the
immunoreaction in protein microarrays and dot blots (Fig. 2). The
majority of AD sera reacted intensely to purified PTCD2 and
FRMD8 protein, while most control sera showed a weak or no
reaction (Figs. 2b, 2d). Dot blot assays independently confirmed
that anti-FRMD8 and anti-PTCD2 antibodies were more
predominant in AD sera than in NDC sera, and so are potentially
useful as diagnostic biomarkers. Continued efforts are needed to
independently confirm the remaining biomarkers.
Discussion
The identification and development of blood-borne biomarkers
for accurate diagnosis and early detection of AD has long been a
central goal. In the present study, we used human protein
microarrays to confirm our earlier discovery using western analysis
that autoantibodies are unexpectedly numerous and perhaps
universally present in human sera. We also demonstrated that the
presence of disease can cause characteristic alterations in serum
autoantibody profiles such that specific autoantibodies and their
cognate antigens can be used effectively as diagnostic biomarkers
of ongoing disease. Lastly, we demonstrate that accurate detection
and diagnosis of AD from a blood sample is possible with only a
small subset of these autoantibody biomarkers.
Autoantibodies Are Numerous in Human Serum
The number of autoantibodies detected in sera using protein
microarrays was found to be surprisingly high, averaging over one
thousand per sample but displaying wide individual variations.
Ascertaining the true number of autoantibodies in individual
serum samples is difficult for several technical reasons. In addition,
any determination of this number employing the protein
microarrays used here will, of course, be an underestimate, since
the available autoantigens represent only about one third of the
estimated human proteome. Regardless of these limitations, it is
clear that the number of autoantibodies in a single serum sample is
much higher than previously thought. The function of such a large
number of autoantibodies is unknown. We suspect that they have
some hitherto unrecognized, but important, role that remains to
be elucidated.
Table 3. Identity and significance of 10 ad vs. Ndc diagnostic biomarkers.
Database ID Description Prevalence in AD Prevalence in Control p
NM_024754.2 Pentatricopeptide repeat domain 2 (PTCD2) 94.23% 14.29% 8.03E-14
BC051695.1 FERM domain containing 8 (FRMD8) 73.08% 4.76% 4.06E-13
NM_018956.2 Chromosome 9 open reading frame 9 (C9orf9) 82.69% 14.29% 3.30E-09
NM_002305.2 Lectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1) 65.39% 9.52% 3.76E-08
NM_000939.1 Proopiomelanocortin (adrenocorticotropin/ beta-lipotropin/ alpha-
melanocyte stimulating hormone/ beta-melanocyte stimulating
hormone/ beta-endorphin) (POMC), transcript variant 2
65.39% 11.91% 1.18E-05
NM_003668.2 Mitogen-activated protein kinase-activated protein kinase 5
(MAPKAPK5), transcript variant 1
71.15% 11.91% 8.91E-09
BC033758.1 Centaurin, alpha 2 (CENTA2) 82.69% 23.81% 5.27E-08
NM_014280.1 DnaJ homolog subfamily C member 8 78.85% 11.91% 9.49E-12
NM_024668.2 Ankyrin repeat and KH domain containing 1 (ANKHD1),
transcript variant 3
73.08% 14.29% 1.05E-06
NM_023937.1 Mitochondrial ribosomal protein L34 (MRPL34), nuclear gene
encoding mitochondrial protein
73.08% 16.67% 3.15E-05
doi:10.1371/journal.pone.0023112.t003
Table 4. Diagnostic accuracies of selected biomarkers.
AD (n=50) vs. Earlier-stage AD (n=35) vs. Later-stage AD (n=15) vs.
All NDC Older Control
Younger
Control PD*
Breast
Cancer All NDC Older Control All NDC Older Control
n=40 n=20 n=20 n=29 n=30 n=40 n=20 n=40 n=20
Sensitivity % 96.0 98.0 98.0 90.0 98.0 97.1 97.1 86.7 93.3
Specificity % 92.5 85.0 90.0 79.3 83.0 92.5 90.0 97.5 90
PPV% 94.1 94.2 96.1 88.2 90.7 91.9 94.4 92.9 87.5
NPV % 94.9 94.4 94.7 82.1 96.2 97.4 94.7 95.1 94.7
*The biomarkers used for this classification are those of Table 5; all others are the biomarkers identified in Table 3.
doi:10.1371/journal.pone.0023112.t004
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Autoantibody Profiles
The present study demonstrates that AD can be linked to
characteristic alterations in serum autoantibody expression
profiles. These changes allow for the identification and selection
of specific autoantibodies that can serve as diagnostic biomarkers.
As exemplified above, with only 10 autoantibody diagnostic
biomarkers, AD serum samples are readily distinguished from
NDC sera with a sensitivity of 96.0% and a specificity of 92.5%.
The fact that these serum autoantibody biomarkers show similar
patterns of reactivity in dot blots spotted with purified, native
proteins further confirms the validity of the immunoreactions on
protein microarrays. We also tested the efficacy of our chosen
biomarkers in differentiating multiple sample demographics of
Table 5. Identity and significance of five AD vs. PD diagnostic biomarkers.
Database ID Description Prevalence in AD Prevalence in PD p
BC051695.1 FERM domain containing 8 (FRMD8) 9.62% 45.16% 5.93E-04
NM_003177.3 Spleen tyrosine kinase (SYK) 19.23% 70.97% 1.35E-05
BC019015.2 Mediator complex subunit 29 (MED29) 9.62% 61.29% 1.61E-06
BC003551.1 Transglutaminase 2 (C polypeptide,
protein-glutamine-gamma-
glutamyltransferase) (TGM2)
13.46% 61.29% 9.67E-05
BC001755.1 Leiomodin-1 26.92% 70.97% 6.84E-05
doi:10.1371/journal.pone.0023112.t005
Figure 2. Differential Expression of PTCD2 and FRMD8 autoantibodies in AD and NDC sera. Microarray fluorescence values reflecting
individual serum autoantibody titers demonstrate a difference in the expression of anti-PTCD2 and anti-FRMD8 in AD (n=50) and NDC (n=40) sera
(a,c). This difference was confirmed in independent dot blots that assessed AD and NDC sera reactivity to purified PTCD2 and FRMD8 protein antigens
(b,d).
doi:10.1371/journal.pone.0023112.g002
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patients from controls with over 90.0% accuracy in all subgroup
comparisons. This successful classification of AD across the full range
o fa v a i l a b l eM M S Esc o r e ss u g g e s t st h a tt h i sa p p ro a c hisu se f u lf o rA D
diagnosis throughout the full course of the disease, and may also be
useful for early detection, perhaps including patients with mild
cognitive impairment and pre-symptomatic disease.
Future work involving more samples should extend our
understanding of autoantibody expression and further optimize
diagnostic success. Many of the samples used in this study were
from living donors, and so their AD was diagnosed using standard
clinical practices [17]. The highest accuracy claimed by these
methods is roughly 90% [18–22] – thus, there is a possibility of
inaccurate sample labeling. As our efforts continue with more
samples and post-mortem validation of AD, the accuracies reported
above should reflect a corresponding increase.
Multiplicity of the AD Diagnostic Panel
Aside from the discovery of so many autoantibodies being present
in the blood, another unexpected finding was that many of these
autoantibodies are differentially expressed in the AD and NDC
groups, and so are potentially useful as diagnostic biomarkers. In fact,
Prospector identified 199 differentiating autoantibodies with a p-value
of less than 0.0001 and group prevalence differences of over 40%.
Importantly, this evaluation of significance was duplicated by the
other statistical algorithms used here, PAM and RF.M o s t
autoantibodies considered significant in one program were repeatedly
selected as significant diagnostic biomarkers by the other two
programs. This finding suggests that many combinations of
autoantibody biomarkers can be used to successfully distinguish AD
sera from NDC sera with varying accuracies. Paradoxically, this
multiplicity of diagnostic indicators often complicates bioinformatic
analyses. The apparent inconsistency of biomarkers selected by
algorithms like RF has been extensively discussed by others [23,24].
This has been blamed on many features of biological data, including
number of variables and relative ‘‘closeness’’ of values. However, as
reported above, we find that there are many relevant autoantibody
biomarkers with diagnostic potential that make possible multiple
‘‘solutions’’ to a single diagnostic question. Thus, in this case, we
contend that what often appears as inconsistency in this type of
analysis might, in fact, simply be the selection of an equally viable set
of biomarkers by the significance analysis programs.
Hypothesis Underlying the Generation of Diagnostic
Autoantibodies
The underlying reason for the presence and abundance of
autoantibodies in human sera, especially in younger and healthy
individuals, is unknown. Although some autoantibodies may be
vestiges of past diseases and reflect a history of immunological
activity, it is clear that many are also present as a result of ongoing
disease. We suggest that active diseases, resulting in cell damage
and death, cause the production and release of antigenic cellular
products. In the case of AD, the somewhat selective early loss of
pyramidal neurons provides a chronic, yet specific, source of such
breakdown products. These products enter the cerebrospinal fluid,
diffuse into the blood and lymph, with some presumably acting as
antigens to elicit an immune response. We propose that this
response leads to the production and appearance of a relatively
large number of autoantibodies in the blood. Since many diseases
exhibit damage to specific cell and tissue types, the biomarker
discovery strategy described here could conceivably be applicable
to the development of successful diagnostics for a wide variety of
diseases.
Potential Benefits of Antigen Identification
One further advantage of using protein microarrays to detect
disease-related autoantibodies in sera is that their antigen targets
also become known. This knowledge may prove to have
therapeutic implications, especially if it sheds new light on
disease-relevant pathways. Such information could be used to
develop therapies that combat pathology by targeting important
members of these pathways. Currently, little is known about the
functions of most of the antigens identified here as targets of the
autoantibody biomarkers for AD. Many of them are explicit only
at the genetic level as elucidated by efforts in creating
comprehensive cDNA libraries [25]. As more is learned about
the functions of autoantibodies in the sera and their targets, we
anticipate that a better understanding of autoantibody profiles will
eventually yield significant therapeutic benefits.
Conclusion
The development of a reliable and accurate blood test for AD
will have profound clinical impact. The identification and use of a
small panel of AD autoantibody biomarkers shown here has a
diagnostic sensitivity of 96.0% and specificity of 92.5% using
available samples. The relative non-invasiveness, low cost, and
dynamism of protein microarrays make a diagnostic of this kind
well-suited for incorporation into routine health care. We hope
that with a diagnostic such as this, accessible early screening
methods can be established so that patients will be better
positioned to avail themselves of effective therapies as they arise.
Acknowledgments
The authors would like to thank Dr. Elizabetta Bini at the Rutgers School
of Environmental and Biological Sciences for her technical help and
generosity during the early phases of this work. The authors also thank
Nimish Acharya for his constant help and encouragement.
Author Contributions
Conceived and designed the experiments: RGN EPN MH BB. Performed
the experiments: EPN MH CD. Analyzed the data: RGN EPN MH CD.
Contributed reagents/materials/analysis tools: RGN BB. Wrote the paper:
RGN EPN MH CD.
References
1. Thies W, Bleiler L (2011) 2011 Alzheimer’s disease facts and figures. Alzheimers
Dement 7: 208–244.
2. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, et al. (2007) Abeta
peptides can enter the brain through a defective blood-brain barrier and bind
selectively to neurons. Brain Res 1142: 223–236.
3. Di Domenico F, Sultana R, Barone E, Perluigi M, Cini C, et al. (2011)
Quantitative proteomics analysis of phosphorylated proteins in the hippocampus
of Alzheimer’s disease subjects. J Proteomics 74: 1091–1103.
4. Dickson DW (1997) Neuropathological diagnosis of Alzheimer’s disease: a perspective
from longitudinal clinicopathological studies. Neurobiol Aging 18: S21–26.
5. Morris JC (2005) Early-stage and preclinical Alzheimer disease. Alzheimer Dis
Assoc Disord 19: 163–165.
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward
defining the preclinical stages of Alzheimer’s disease: recommendations from the
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers Dement 7: 280–292.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., et al.
(2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations
from the National Institute on Aging-Alzheimer’s Association workgroups on
diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7: 263–269.
8. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, et al. (2010) Brain-
reactive autoantibodies are nearly ubiquitous in human sera and may be linked
to pathology in the context of blood-brain barrier breakdown. Brain Res 1345:
221–232.
Autoantibodies and Alzheimer’s Disease Diagnosis
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e231129. Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, et al. (2011) Brain-
reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-
beta1-42 deposition. J Alzheimers Dis;In press.
10. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple
cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A
99: 6567–6572.
11. Breiman L (2001) Random Forests. Machine Learning 45: 5–32.
12. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, et al. (2011)
Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic
model of Parkinson’s disease. Eur J Neurosci 33: 1598–1610.
13. Cheng F, Vivacqua G, Yu S (2010) The role of alpha-synuclein in
neurotransmission and synaptic plasticity. J Chem Neuroanat: In press.
14. Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with
Parkinson’s disease. Brain Pathol 20: 633–639.
15. Strobel G (2009) The spectrum series: grappling with the overlap between
Alzheimer’s and Parkinson’s diseases. 9th International Conference on
Alzheimer’s and Parkinson’s Diseases, 11–15 March 2009, Prague,Czech
Republic. J Alzheimers Dis 18: 625–640.
16. DeKosky ST, Marek K (2003) Looking backward to move forward: early
detection of neurodegenerative disorders. Science 302: 830–834.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34: 939–944.
18. Lopponen M, Raiha I, Isoaho R, Vahlberg T, Kivela SL (2003) Diagnosing
cognitive impairment and dementia in primary health care – a more active
approach is needed. Age Ageing 32: 606–612.
19. Ranginwala NA, Hynan LS, Weiner MF, White CL, 3rd (2008) Clinical criteria
for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr
Psychiatry 16: 384–388.
20. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, et al. (1998) Utility of the
apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s
Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease.
N Engl J Med 338: 506–511.
21. Jobst KA, Barnetson LP, Shepstone BJ (1998) Accurate prediction of
histologically confirmed Alzheimer’s disease and the differential diagnosis of
dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-
ray CT, and Apo E4 in medial temporal lobe dementias. Int Psychogeriatr 10:
271–302.
22. Aretouli E, Brandt J (2010) Episodic memory in dementia: Characteristics of
new learning that differentiate Alzheimer’s, Huntington’s, and Parkinson’s
diseases. Arch Clin Neuropsychol 25: 396–409.
23. Diaz-Uriarte R, Alvarez de Andres S (2006) Gene selection and classification of
microarray data using random forest. BMC bioinformatics 7: 3.
24. Lubomirski M, D’Andrea MR, Belkowski SM, Cabrera J, Dixon JM, et al.
(2007) A consolidated approach to analyzing data from high-throughput protein
microarrays with an application to immune response profiling in humans.
J Comput Biol 14: 350–359.
25. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, et al. (2004)
The status, quality, and expansion of the NIH full-length cDNA project: the
Mammalian Gene Collection (MGC). Genome Res 14: 2121–2127.
Autoantibodies and Alzheimer’s Disease Diagnosis
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23112